A new cold chain container that’s small and ideal to meet growing demand for sensitive cargo capacity is set to revolutionise the market for urgent transportation, says the company behind the innovation, Tower Cold Chain.
The UK-based developers believe the temperature-controlled transportation of pharmaceuticals, life-science and biotech products is now even easier thanks to what it calls the KTEvolution.
The easy-to-carry container – it can be carried by one or two people – is “a robust, lightweight, handleable solution with the same reliable thermal protection and reusable durability of our existing container range”, Tower says.
“The introduction of KTEvolution adds to our existing product portfolio which offers a solution for easy, cost-effective and compliant transport of pharmaceutical products between suppliers, manufacturers, distributors and end patients throughout the global supply chain.”
At a “cold chain life” of 120 hours, the container adds at least a day to the general standard of 96 hours.
Tower has reason to view the KTEvolution as an important contributor to its existing range of containers.
According to data collected from 25 000 shipments, the company’s range of cold chain boxes has a 0.1% “temperature excursion” – the rate at which temperature-sensitive pharmaceutical products deviate from given instructions, according to the WHO.
Tower said the container “fills a gap in the cold chain shipping market – ideal for the growing trend in smaller shipments such as direct-to-patient, samples shipment, and last-mile deliveries”.
The company’s global head of product development, Mark Hawes, said: ““Pharmaceutical manufacturers, 3PL providers, and airlines value the consistency and stability assured when shipping products in Tower containers.”
The KTEvolution will be launched in 26- and 57-litre options, offering extra capacity compared to the regular 5-25 litres of similar urgent biotech cargo containers.
For more information, read the article in our Knowledge Library: https://tinyurl.com/39kvj5hd